ANIP
ANI PHARMACEUTICALS INCCompany Information
- Company Name
- ANI PHARMACEUTICALS INC
- CIK
- CIK0001023024
- Category
- Large accelerated filer
- Ticker: Exchange
- ANIP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANIP
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-29
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 167,574
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 22,608,524
- Shares outstanding
- 21,158,000
- Ownership
- 106.86%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -6.93%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 360 | 311 | 286 | 263 | 218 | 150 | 145 | 145 | 240 | 229 | 221 | 193 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | ||||||
| Accounts Receivable Net Current | 274 | 255 | 281 | 253 | 226 | 220 | 222 | 196 | 166 | 172 | 162 | 179 | ||||||
| Inventory Net | 143 | 143 | 143 | 146 | 138 | 137 | 137 | 148 | 125 | 114 | 111 | 107 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 8 | 8 | ||||||
| Prepaid Expense Current | 32 | 22 | 23 | 19 | 15 | 23 | 18 | 17 | 14 | 16 | 17 | 11 | ||||||
| Equity Securities Fv Ni Cost | 16 | 15 | 9 | 9 | 6 | 5 | 6 | 8 | 7 | 10 | 0 | - | ||||||
| Assets Current | 825 | 747 | 753 | 698 | 603 | 536 | 528 | 521 | 555 | 541 | 520 | 497 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 73 | 67 | 62 | 64 | 59 | 58 | 57 | 57 | 52 | 49 | 45 | 44 | ||||||
| Deferred Income Tax Assets Net | 71 | 67 | 69 | 71 | 92 | 88 | 85 | 68 | 90 | 88 | 91 | 84 | ||||||
| Intangible Assets Net Excluding Goodwill | 450 | 467 | 480 | 500 | 520 | 538 | 542 | 570 | 183 | 196 | 209 | 220 | ||||||
| Goodwill | 62 | 62 | 62 | 62 | 61 | 61 | 60 | 60 | 28 | 28 | 28 | 28 | ||||||
| Other Assets Noncurrent | 12 | 12 | 14 | 12 | 8 | 10 | 12 | 11 | 13 | 14 | 12 | 16 | ||||||
| Assets | 1,494 | 1,422 | 1,440 | 1,408 | 1,343 | 1,292 | 1,284 | 1,287 | 921 | 915 | 904 | 890 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 74 | 70 | 63 | 70 | 55 | 53 | 46 | 61 | 49 | 49 | 37 | 34 | ||||||
| Accrued Royalties Current | 56 | 34 | 48 | 51 | 36 | 24 | 23 | 23 | 20 | 15 | 16 | 12 | ||||||
| Employee Related Liabilities Current | 27 | 16 | 38 | 33 | 33 | 22 | 38 | 30 | 16 | 10 | 24 | 15 | ||||||
| Accrued Liabilities Current | 17 | 14 | 17 | 14 | 15 | 12 | 14 | 18 | 7 | 7 | 6 | 5 | ||||||
| Taxes Payable Current | 4 | 5 | 1 | 0 | 3 | 14 | 6 | 0 | 0 | 11 | 8 | 1 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 12 | 24 | ||||||
| Long Term Debt Current | 21 | 19 | 17 | 15 | 13 | 11 | 9 | 7 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 284 | 240 | 278 | 271 | 237 | 202 | 194 | 190 | 140 | 137 | 145 | 134 | ||||||
Long Term Debt Noncurrent | ||||||||||||||||||
| Long Term Debt Noncurrent | 280 | 286 | 292 | 298 | 301 | 305 | 309 | 313 | 284 | 285 | 285 | 285 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 9 | 9 | 10 | 11 | 18 | 17 | 20 | 20 | 11 | 11 | 12 | 11 | ||||||
| Other Liabilities Noncurrent | 16 | 16 | 12 | 11 | 7 | 7 | 6 | 7 | 5 | 5 | 5 | 5 | ||||||
| Liabilities | 897 | 860 | 900 | 902 | 881 | 849 | 856 | 857 | 440 | 438 | 447 | 435 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Temporary Equity | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | 0 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Treasury Stock Common Value | -54 | -53 | -33 | -33 | -32 | -31 | -21 | -21 | -20 | -19 | -10 | -10 | ||||||
| Additional Paid In Capital | 620 | 608 | 596 | 586 | 542 | 531 | 520 | 511 | 532 | 524 | 514 | 507 | ||||||
| Retained Earnings Accumulated Deficit | 31 | 6 | -23 | -51 | -77 | -85 | -100 | -90 | -65 | -62 | -80 | -81 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 1 | 3 | 3 | 4 | 5 | 5 | 8 | 9 | 9 | 14 | ||||||
| Stockholders Equity | 597 | 562 | 541 | 506 | 437 | 419 | 404 | 406 | 456 | 452 | 433 | 430 | ||||||
| Liabilities And Stockholders Equity | 1,494 | 1,422 | 1,440 | 1,408 | 1,343 | 1,292 | 1,284 | 1,287 | 921 | 915 | 904 | 890 | ||||||
| Convertible Preferred Stock | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 0 | 0 | ||||||
| Common Stock | 0 | 23 | 0 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Class C Special Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Valuation Allowances And Reserves Balance | - | - | 172 | 125 | 120 | 140 | 128 | 91 | 103 | 92 | 97 | 98 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | ||||||
| Common Stock Shares Authorized | - | - | 66 | - | - | - | 33 | - | - | - | - | - | ||||||
| Common Stock Shares Issued | - | - | 23 | - | - | - | 22 | - | - | - | - | - | ||||||
| Shares Outstanding | - | - | 22 | - | - | - | 21 | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialANI PHARMACEUTICALS INC (ANIP) — SEC Financial Statements & Analysis
ANI PHARMACEUTICALS INC (ANIP) is a pharmaceutical preparations company, incorporated in DE. ANI PHARMACEUTICALS INC trades on Nasdaq as: ANIP. ANI PHARMACEUTICALS INC (ANIP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, ANI PHARMACEUTICALS INC carries a market cap of $1.75B, a P/E ratio of 16.36x, a P/B ratio of 2.93x, a P/S ratio of 1.79x, an enterprise value of $1.69B, and an EV/EBITDA multiple of 7.17x. On profitability, it posts a gross margin of 60.40%, an operating margin of 15.37%, a net margin of 10.94%, a Return on Equity (ROE) of 20.71%, a Return on Assets (ROA) of 7.55%, and a Return on Invested Capital (ROIC) of 20.64%. Per share, it reports EPS of $5.06, diluted EPS of $4.89, free cash flow per share of $8.18, and a dividend per share of $0.02. Over the trailing year, it posted revenue growth of 30.90% year-over-year, net income growth of -946.03% year-over-year, and EPS growth of -893.09% year-over-year. On the balance sheet, it maintains a current ratio of 2.91x, a quick ratio of 2.29x, working capital of $541.78M, a debt-to-equity ratio of 1.50x, a debt ratio of 0.6, an interest coverage ratio of 9.09x, free cash flow of $172.99M (TTM), and net debt of $-58.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.75B
- P/E TTM
- 16.36x
- EPS TTM
- $5.06
- P/B TTM
- 2.93x
- ROE TTM
- 20.71%
- ROA TTM
- 7.55%
- Debt To Equity
- 1.50x
- Free Cash Flow TTM
- $172.99M
- Net Revenue TTM Growth 1Y
- 30.90%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ANI PHARMACEUTICALS INC in?
ANI PHARMACEUTICALS INC (ANIP) operates in the Pharmaceutical Preparations industry.
What exchange does ANIP trade on?
ANI PHARMACEUTICALS INC (ANIP) trades on the Nasdaq.
Where is ANI PHARMACEUTICALS INC incorporated?
ANI PHARMACEUTICALS INC is incorporated in DE.
When was ANI PHARMACEUTICALS INC (ANIP)'s most recent SEC filing?
ANI PHARMACEUTICALS INC (ANIP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ANIP's market cap?
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of $1.75B as of 2026-06-30.
What is ANIP's P/E ratio?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month P/E ratio is 16.36x as of 2026-06-30.
What is ANIP's EPS (earnings per share)?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month EPS is $5.06 as of 2026-06-30.
What is ANIP's ROE (return on equity)?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month Return on Equity (ROE) is 20.71% as of 2026-06-30.
What is ANIP's ROA (return on assets)?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month Return on Assets (ROA) is 7.55% as of 2026-06-30.
What is ANIP's ROIC (return on invested capital)?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month Return on Invested Capital (ROIC) is 20.64% as of 2026-06-30.
What is ANIP's EV/EBITDA?
ANI PHARMACEUTICALS INC (ANIP)'s trailing twelve month EV/EBITDA is 7.17x as of 2026-06-30.